Business Context and Reporting Period
Lisata Therapeutics, Inc. (Lisata) filed a Form 8-K on January 20, 2026, announcing the entry into a binding Term Sheet with Kuva Labs Inc. (Kuva). The agreement outlines a proposed acquisition of Lisata by Kuva via a tender offer followed by a short-form merger. The Lisata Board of Directors unanimously recommended the transaction as fair and in the best interests of stockholders.
Key Financial Metrics and Transaction Terms
This filing details a proposed transaction rather than periodic financial results. Key financial terms include:
- Offer Price: $4.00 per share in cash for all outstanding shares of common stock.
- Contingent Value Rights (CVRs): Two non-tradeable CVRs per share, with potential payouts of:
- $1.00 per share within 12 months of rights to certepetide in Greater China reverting to Lisata.
- $1.00 per share upon filing of an NDA or similar registration document for certepetide in any jurisdiction.
- Breakup Fee: $2,000,000 payable by either party under specific termination scenarios (e.g., failure to enter a Purchase Agreement by February 27, 2026, or termination for a superior proposal).
- Financing: Kuva represented that the offer is not conditioned on financing and has obtained funding commitments sufficient to cover obligations, subject to diligence and definitive terms.
The filing does not provide current revenue, profit, cash flow, or debt figures for Lisata.
Material Changes and Operational Covenants
Upon execution of the Term Sheet, Lisata agreed to specific operational restrictions until the entry into a definitive Purchase Agreement or termination:
- Exclusivity: Lisata is restricted from soliciting competing transactions for 30 days or until the Purchase Agreement is signed, subject to a fiduciary "fiduciary out" for superior proposals.
- Spending Cap: Monthly spend must not exceed the average monthly spend for the 2025 fiscal year, with specific exclusions for transaction expenses, D&O insurance, existing compensation, regulatory compliance, and clinical studies.
- Equity Issuance: Lisata is prohibited from issuing equity securities (including options and RSUs) or entering into change-of-control bonus arrangements.
- Standstill: Kuva is restricted from acquiring additional Lisata securities or initiating other business combinations for 12 months, unless the Term Sheet is terminated.
Outlook, Risks, and Contingencies
The transaction is subject to the negotiation and execution of a definitive Purchase Agreement by February 27, 2026. Key risks and contingencies include:
- Closing Conditions: The tender offer requires the valid tender of shares representing a majority of the aggregate voting power.
- Material Adverse Effect (MAE): The agreement defines MAE broadly but excludes general economic conditions, pandemics, changes in stock price, and specifically excludes adverse outcomes from clinical trial programs or studies.
- Regulatory Filings: The tender offer has not yet commenced. Kuva must file a Schedule TO, and Lisata must file a Schedule 14D-9 before the offer begins.
- Forward-Looking Uncertainties: Risks include the possibility of competing offers, failure to satisfy closing conditions, disruption to business operations, and stockholder litigation.
Investor Verification Checklist
- Verify the definitive Purchase Agreement terms once filed, specifically regarding the final consideration and closing conditions.
- Review the upcoming Schedule 14D-9 for the Board's formal recommendation and the Schedule TO for the full tender offer terms.
- Confirm the status of Kuva's third-party funding commitments and whether they remain subject to diligence.
- Monitor the timeline for the February 27, 2026, deadline for entering the Purchase Agreement to assess the risk of the $2 million breakup fee.
- Assess the likelihood of the CVR triggers (reversion of Greater China rights and NDA filing) based on current clinical and commercial progress.